BioSpace News Archive

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, received an official communication from the China National Intellectual Property Administration (“CNIPA”) regarding its intention to grant Chinese Patent Application No. 201380021092.5. Including thi

Financing to drive development and commercialization of innovative cell & gene therapy processing solution

Investigational drug, ARMS-I, manufactured by ARMS Pharmaceutical may prevent airborne transmission of coronavirus

Expands Biocept’s intellectual property globally for methods of detecting rare mutations, including cancer biomarkers associated with circulating tumor DNA (ctDNA)

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced the receipt of a CE-mark for its sterile biodegradable sealant in a pre-filled syringe.

Axial Biotherapeutics announced positive topline data from its Phase 1b/2a clinical trial of AB-2004, a first-in-class therapeutic that removes certain metabolites from the gastrointestinal tract for the treatment of Autism Spectrum Disorder.

Eyenuk, Inc., a global artificial intelligence medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced that it completed the first quarter of 2020 with encouraging business results.

Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEV TM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Based on recent dis

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.

Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today ann